Consistently, the decreased growth and weight of USP1-deficient tumors were significantly restored by MAX or MYC overexpression in the mouse model of rituximab/chemotherapy resistant DLBCL (Fig. 5c, d). Here, MYC is linked to diffuse large B-cell lymphoma.